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Abstract: Nanofiber scaffolds formed by self-assembling peptide RADA16-I have been 
used for the study of cell proliferation to mimic an extracellular matrix. In this study, we 
investigated the effect of RADA16-I on the growth of human leukemia cells in vitro and in 
nude mice. Self-assembly assessment showed that RADA16-I molecules have excellent 
self-assembling ability to form stable nanofibers. MTT assay displayed that RADA16-I has 
no cytotoxicity for leukemia cells and human umbilical vein endothelial cells (HUVECs) 
in vitro. However, RADA16-I inhibited the growth of K562 tumors in nude mice. 
Furthermore, we found RADA16-I inhibited vascular tube-formation by HUVECs in vitro. 
Our data suggested that nanofiber scaffolds formed by RADA16-I could change tumor 
microenvironments, and inhibit the growth of tumors. The study helps to encourage further 
design of self-assembling systems for cancer therapy. 
Keywords: self-assembling peptide RADA16-I; nanofiber scaffolds; mimic extracellular 
matrix; tumor microenvironments; cancer therapy 
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1. Introduction 
 
For a long time, many efforts have focused on the inhibition and destruction of cancer cells for 
cancer treatment, but unfortunately, because of drug cytotoxicity and resistance developed in cancer 
cells, the applications of many traditional anticancer drugs are generally accompanied with 
inefficiencies and severe side effects [1,2]. 
Recently, researchers realized that solid tumors are organ-like structures in various 
microenvironments; cancer cells are embedded in an extracellular matrix and nourished by a vascular 
network. These microenvironments not only allow interactions among cancer cells and between cancer 
cells and the basal membrane, but also remove waste products. Substantial studies have determined 
that tumor microenvironments are critical for the proliferation of tumor cells and their response to 
anticancer drugs [3-5]. Thus, strategies to modulate the tumor microenvironments (including the tumor 
vasculature) could offer additional approaches for cancer treatment. 
Previous studies have discovered that self-assembling peptide systems [6-13], made from natural 
amino acids, can spontaneously assemble into nanofiber scaffolds, which comprise numerous 
nanofibers of ~ 10 nm diameter and nanopores between 5 – 200 nm [6-8]. These peptide scaffolds have 
three-dimensional nanofiber structures similar to the natural extracellular matrix. Consequently, they 
have been used for the study of cell attachment and proliferation as biomimic synthetic extracellular 
matrix [7,9,10]. 
The self-assembling peptide RADA16-I (Ac-RADARADARADARADA-CONH2), a simple model 
oligopeptide, is characterized by the regular repeats of alternating ionic hydrophilic and hydrophobic 
amino acids, and usually forms stable a β-sheet structure in water. RADA16-I molecules can not only 
spontaneously self-assemble to form stable nanofibers, but also form higher-order nanofiber scaffolds 
in the presence of monovalent cations or physiological media [8]. Here, we asked whether nanofiber 
scaffolds formed by RADA16-I could change the tumor microenvironments as biomimetic 
extracellular matrix, and influence the growth of tumors.  
In this study, we firstly confirmed the self-assembling ability of RADA16-I by using atomic force 
microscopy (AFM). Secondly, MTT assay was performed to examine the effect of RADA16-I on the 
proliferation of human leukemia cells and human umbilical vein endothelial cells (HUVECs) in vitro. 
We next examined the inhibition of RADA16-I against human leukemia xenograft growth in nude 
mice. Finally, we evaluated the in vitro effect of RADA16-I on the vascular tube-formation by 
HUVECs, which are critical to form new capillaries in the vicinity of solid tumors and promote the 
formation of three-dimensional vascular tubes [14,15]. 
 
2. Results and Discussion 
 
2.1. Self-assembly Assessment of RADA16-I 
 
The self-assembling peptide RADA16-I (Figure 1) is a self-complementary peptide, which forms 
stable β-sheet structure in aqueous solution with two distinct surfaces—one hydrophilic, the other 
hydrophobic. All the hydrophobic alanine residues shield themselves from water and self-assemble on 
the hydrophobic surface, on the other hand, arginine and aspartic acid residues can form 
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complementary ionic bonds with regular repeats on the hydrophilic surface. Based on these 
intermolecular forces, RADA16-I molecules can spontaneously self-assemble to form stable 
nanofibers and higher-order nanofiber scaffolds in physiological media. 
Figure 1. Schematic molecular model of Peptide RADA16-I. RADA16-I has regular 
repeats of ionic hydrophilic and hydrophobic amino acids, and forms stable β-sheet 
structure in aqueous solution with two distinct surfaces — hydrophilic surface and 
hydrophobic surface. All the hydrophobic alanine residues form the hydrophobic surface, 
arginine and aspartic acid residues constitute the hydrophilic surface with regular repeats. 
The dimensions of the RADA16-I molecule are about 5 nm in length, 1.3 nm in height, and 
0.8 nm in width [16]. 
 
 
In this study, the nanostructure of RADA16-I was observed by using AFM (Tapping Mode) at 
different scales (5 × 5 µm2, 2 × 2 µm2 and 1 × 1 µm2). As shown in Figure 2, dense nanofibers formed 
by RADA16-I were observed, a result consistent with a previous study [17]. The result confirms that 
peptide RADA16-I has excellent self-assembling ability to form nanofibers and higher-order  
nanofiber scaffolds. 
Figure 2. AFM images of RADA16-I. The working solution of RADA16-I was prepared at 
100 µM concentration by using Milli-Q water. The nanostructure of RADA16-I was 
scanned at different scales, 5 × 5 µm2 (A), 2 × 2 µm2 (B) and 1 × 1 µm2 (C). Dense 
nanofibers were observed, indicating peptide RADA16-I has excellent self-assembling 
ability to form nanofiber scaffolds. 
 
 
2.2. Cytotoxicity Assays in vitro 
 
Previous studies have shown that nanofiber scaffolds formed by self-assembling peptides have no 
cytotoxicity, and support the attachment and growth of a variety of mammalian primary cells in tissue 
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culture [6-8]. Similarly, RADA16-I is nontoxic and supports not only the growth of cells [8], but also 
tissue regeneration [18]. The results of a MTT assay are consistent with early studies, showing that 
RADA16-I had no cytotoxicity for both K562 and Jurkat cells even at 2 mM peptide concentration; the 
relative viabilities were 101.66 ± 4.25% for K562 cells and 97.44 ± 5.66% for Jurkat cells (Figure 3A). 
RADA16-I even promoted the growth of leukemia cells at lower peptide concentrations (Figure 3A). 
Moreover, MTT assay also showed that RADA16-I had no cytotoxicity against HUVECs, there was 
almost no reduction in HUVEC viability (90 – 100% viability) after treatment with peptide RADA16-I 
at varying concentrations ((10 – 80μM) (Figure 3B). Taken together, the results of MTT assay 
suggested that peptide RADA16-I had an excellent biocompatibility without obvious cytotoxicity as 
described [8,18].  
Figure 3. Cytotoxicity of RADA16-I against human leukemia cells and HUVECs by MTT 
proliferation assay. (A) MTT assay showed that RADA16-I had no cytotoxicity for both 
K562 and Jurkat cells. After treated with RADA16-I solution at the maximal concentration 
(2mM), the relative viabilities of K562 and Jurkat cells were 101.66 ± 4.25% and 97.44 ± 
5.66%, respectively. RADA16-I solutions at lower concentrations even enhanced the 
proliferation of cells. (B) MTT assay displayed that RADA16-I had almost no cytotoxicity 
against HUVECs even at 80 μM peptide concentration (92.90 ± 3.54% viability). Data 
shown are Means ± SD. 
 
 
2.3. Inhibition of RADA16-I on K562 Tumor Growth in vivo 
 
After examining the cytotoxicity of RADA16-I against leukemia cells in vitro, we further analyzed 
the effect of RADA16-I on the growth of K562 tumors in nude mice. After the sixth treatment, we 
found that the average tumor weight (1.51 ± 0.08 g) in RADA16-I treatment group had been markedly 
decreased, compared with that (2.72 ± 0.50 g) in a control group (Figure 4A). Other than these effects, 
animals treated with RADA16-I were normal and did not show any sign of physical weakness 
throughout the experiment. Finally, tumors were fixed with formaldehyde, and sectioned for 
histological examination by H&E staining. As shown in Figure 4B, H&E staining showed that mass 
proliferation existed in tumor cells from control mice, whereas the structural pattern of tumors treated 
with RADA16-I was replaced by massive cell death in which the cells were characterized by 
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acidophilic homogeneous masses without nuclei. These data suggested that RADA16-I could inhibit 
the K562 tumor growth in vivo though peptide has no cytotoxicity against cancer cells in vitro. 
Figure 4. Effect of RADA16-I on K562 tumor growth. We analyzed the effect of 
RADA16-I on K562 tumor growth by using mouse models. (A) After treatment with 
RADA16-I, average tumor weight in treatment group (1.51 ± 0.08 g) was markedly 
decreased as compared with that in control group (2.72 ± 0.50 g), data shown are Means ± 
SEM, P < 0.05. (B) Histological examination of tumors. Tumors were fixed with 
formaldehyde, and sectioned for histological examination by H & E staining. H & E 
staining showed that massive cell death existed in tumors treated by RADA16-I compared 
with the controls. These results suggested that RADA16-I could inhibit the K562 tumor 
growth in vivo. 
 
 
2.4. Inhibition of Vascular Tube-formation by RADA16-I 
 
The formation of new capillaries by HUVEC is critical for the migration of endothelial cells and the 
formation of neovascularization [14]. In our study, we evaluated the effect of RADA16-I on tube 
formation by HUVECs. As seen in Figure 5, HUVECs without peptide treatment migrated to form a 
well-arranged network of tubes within 9 h, while this effect was significantly decreased in the presence 
of RADA16-I. After treated with 20 μM or 40 μM RADA16-I, the endothelial network-like structures 
were broken. Furthermore, treatment with 60 μM or 80 μM RADA16-I yielded maximal inhibition 
with the almost complete absence of tube formation. However, MTT assay showed that RADA16-I is 
nontoxic to HUVECs even at 80 μM peptide concentration (Figure 3B), suggesting the inhibition of 
vascular tube-formation is not caused by cell death or cytotoxicity. Taken together, these results 
indicated that RADA16-I could inhibit the formation of neovascularization without cytotoxic effect, 
and consequently lead to prevention of tumor growth. 
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Figure 5. Inhibition of vascular tube-formation in vitro. We evaluated the effect of 
RADA16-I on the tubes formation by HUVECs in vitro. (A) HUVECs treated with control 
solution can migrate to form a well-arranged network of tubes within 9 h. After treated 
with 20 μM (B) or 40 μM (C) RADA16-I, the network-like structures were broken. 
Treatment with 60 μM (D) or 80 μM (E) RADA16-I completely inhibited the tube 
formation. These data suggested that RADA16-I could inhibit the formation of  
vascular tubes. 
 
 
3. Experimental Section 
 
3.1. Preparation of Peptide RADA16-I 
 
The peptide RADA16-I (PuraMatrixTM, Ac-RADARADARADARADA-CONH2) was purchased 
from BD Bioscience (Bedford, MA, USA). The working solutions of RADA16-I were prepared at 
different concentrations with sterile water (18 MΩ; Millipore Milli-Q system) and stored at 4 °C.  
 
3.2. Cell Cultures 
 
Human umbilical vein endothelial cells (HUVECs) were isolated from human umbilical cord tissue 
by collagenase digestion as described previously [19]. The harvested cells were plated on gelatin-
coated culture bottles in medium 199 containing 20% fetal calf serum, basic fibroblast growth factor 
(bFGF, 10 ng/mL), vascular endothelial growth factor (VEGF, 2 ng/mL), 200 U/mL penicillin and  
200 μg/mL streptomycin. After 3 – 4 passages, HUVECs were collected to use. Two human leukemia 
cell lines, K562 and Jurkat, were grown in RPMI 1640 medium supplemented with 10% fetal calf 
serum and antibiotics (100 units/mL penicillin G, 100 μg/mL streptomycin). All cell lines were 
incubated at 37 °C in a 5% CO2 humidified atmosphere.  
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3.3. Self-Assembly Assessment of RADA16-I with Atomic Force Microscopy 
 
RADA16-I working solution was prepared at a concentration of 100 μM with Milli-Q water. 
Approximately 5 μL of RADA16-I solution was evenly deposited onto a freshly cleaved mica surface 
at room temperature. After 30 seconds, the mica surface was rinsed with 1,000 µL of Milli-Q water to 
remove unattached peptides. Sample on the mica surface was then air-dried and scanned by Atomic 
Force Microscopy (AFM) in air. 
AFM images were collected by using the tapping mode on a SPI4,000 Probe Station & SPA-400 
SPM Unit (Seiko Instruments Inc., Chiba, Japan). All images were acquired by utilizing a 20 µm 
Scanner (400) and an Olympus Si-DF20 microcantilever as well as tip (Si, tip radius 10 nm, 
rectangular base 200.00 µm) with the spring constant of 12.00 N/m. The cantilever’s free resonance 
frequency is 127.00 KHz. To show the nanostructure formed by self-assembling peptide RADA16-I, 
AFM images were scanned and collected at 5 × 5 µm2, 2 × 2 µm2 and 1 × 1 µm2 scales. 
 
3.4. MTT Proliferation Assay 
 
The effect of RADA16-I on the viability of human leukemia cells and HUVECs in vitro was 
assessed by a MTT assay [20]. Briefly, cells in 100 µL of fresh medium were seeded onto 96-well 
plates at a density of 5 × 103 cells/well for K562, 2 × 104 cells/well for Jurkat and 1 × 104 cells/well for 
HUVECs, respectively. After 24 h incubation at 37 °C, 10 µL of RADA16-I solution and control 
solution (sterile water) were added and incubated for 48 h. Thereafter, 20 µL of MTT reaction solution 
(5 mg/mL MTT in PBS; Sigma) was added to each well, and the plates were incubated at 37 °C for  
4 h. 10% SDS solution (100 µL) containing 0.01 M HCL was immediately added to each well to 
solubilize deposit and the plates were incubated overnight. Spectrometric absorbance was measured at 
570 nm by a μQuant microplate reader (Bio-Tek). Cell viability was determined relative to the control.  
 
3.5. Inhibition of RADA16-I against K562 Tumor Growth in Mice 
 
BALB/c nude mice (4-6 weeks) were obtained from the Experimental Animal Center, Sichuan 
University. Approximately 1 × 107 K562 cells suspended in 200 μL of serum-free culture medium 
RPMI 1,640/Matrigel mixture (1:1) were injected s.c. into the right flank of nude mice. Four days after 
implantation, solid tumor formed. The mice were then randomly assigned into two groups, RADA16-I 
treatment group and control group. Each group contained seven mice aged 5 – 6 weeks. In treatment 
group, RADA16-I solution (2 mM, 0.1 mL) was injected to the brim of the tumors every 3 days. 
Parallel experiments were performed in control group, in which 0.1 mL of sterile water without 
peptide was injected in the same manner. Mice were sacrificed 18 days after the first treatment to 
measure tumor masses and to perform histological examination by H & E staining. 
 
3.6. Vascular Tube Formation Assay in vitro 
 
Vascular tube formation assay in vitro was performed according to the previous description [14,15]. 
Briefly, 96-well plates were coated with Matrigel (0.05 mL) and incubated at 37 °C for 1 h to promote 
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gelling. HUVECs suspension (1.4 × 104 cells/well) were seeded on the Matrigel and treated with 
RADA16-I solutions at various concentrations for 9 h. Phase-contrast microscope (Olympus IX71, 
Tokyo, Japan) was used to record tube formation by HUVECs. 
 
3.7. Statistical Analysis 
 
Statistical analysis was performed by using the SPSS 13.0 for windows package, and student’s t test 
was used to determine statistical significance.  
 
4. Conclusions  
 
We have investigated the self-assembling ability of peptide RADA16-I and its effect on the growth 
of human leukemia cells in vitro and in vivo. AFM images showed that peptide RADA16-I molecules 
have excellent self-assembling ability to form nanofiber scaffolds, which have been used as a 
biomimetic extracellular matrix. Most importantly, the study demonstrated that RADA16-I molecules 
inhibit the growth of K562 tumors in nude mice though they have no cytotoxicity against cancer cells 
in vitro. Furthermore, we found that RADA16-I inhibited the vascular tube-formation by HUVECs 
without cytotoxic effect in vitro. Taken together, our data indicated that RADA16-I molecules self-
assemble into nanofiber scaffolds, which could change tumor microenvironments (including vascular 
tubes), and inhibit the growth of tumors. This study reveals the feasibility of designing novel 
nanomaterials based on self-assembling systems for cancer treatment.  
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